CIK 0000875045
- Large accelerated filer
BIOGEN INC.
Sign in to watch- Ticker
- BIIB
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 330112644
- Phone
- +1 617-679-2000
- Business address
- 225 BINNEY STREET, CAMBRIDGE, MA, 02142
- Former names
- BIOGEN IDEC INC., BIOGEN IDEC INC, IDEC PHARMACEUTICALS CORP / DE, IDEC PHARMACEUTICALS CORP / CA
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2019-06-01 | Ehlers Michael D EVP, Research and Development | Option exercise | +1,126 | 8,525.22 | ||
| 2019-06-01 | Ehlers Michael D EVP, Research and Development | Shares withheld for taxes | −500 | $219.29 | $110K | 8,025.22 |
| 2019-06-01 | Ehlers Michael D EVP, Research and Development | Option exercise · Restricted Stock Unit | −1,126 | 1,376 | ||
| 2019-06-01 | Ehlers Michael D EVP, Research and Development | Other disposition · Restricted Stock Unit | −1,376 | 0 | ||
| 2019-05-02 | Vounatsos Michel Chief Executive Officer | Option exercise | +1,480 | 22,487.32 | ||
| 2019-05-02 | Vounatsos Michel Chief Executive Officer | Shares withheld for taxes | −658 | $230.52 | $152K | 21,829.32 |
| 2019-05-02 | Vounatsos Michel Chief Executive Officer | Option exercise · Restricted Stock Unit | −1,480 | 1,772 | ||
| 2019-05-02 | Vounatsos Michel Chief Executive Officer | Other disposition · Restricted Stock Unit | −1,772 | 0 | ||
| 2019-05-02 | DENNER ALEXANDER J Director | Purchase | +38,000 | $231.24 | $8.8M | 643,000 |
| 2019-05-01 | DENNER ALEXANDER J Director | Purchase | +30,000 | $229.46 | $6.9M | 605,000 |
| 2019-05-01 | Vounatsos Michel Chief Executive Officer | Purchase | +4,351 | $231.48 | $1.0M | 21,007.32 |
| 2019-04-30 | DENNER ALEXANDER J Director | Purchase | +50,342 | $229.25 | $11.5M | 575,000 |
| 2019-03-18 | PANGIA ROBERT W Director | Option exercise | +6,114 | $52.22 | $319K | 24,701 |
| 2019-03-18 | PANGIA ROBERT W Director | Sale | −6,114 | $328.55 | $2.0M | 18,587 |
| 2019-03-18 | PANGIA ROBERT W Director | Option exercise · Stock Option (Right to Buy) | −6,114 | 0 | ||
| 2019-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Shares withheld for taxes | −405 | $334.10 | $135K | 6,919.63 |
| 2019-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Option exercise | +568 | 7,487.63 | ||
| 2019-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Shares withheld for taxes | −253 | $334.10 | $85K | 7,234.63 |
| 2019-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Option exercise · Restricted Stock Unit | −568 | 280 | ||
| 2019-03-01 | McKenzie Paul EVP Pharmaceutical Oper & Tech | Other disposition · Restricted Stock Unit | −280 | 0 |
Page 49 of 61 · 1,204 trades